A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity
Status:
Terminated
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, single-arm study evaluating the safety and efficacy of
defibrotide for the prevention of CAR-T-associated neurotoxicity in subjects with relapsed or
refractory diffuse large B-cell lymphoma (DLBCL) receiving Yescarta.